Literature DB >> 29722811

Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors.

David R Bakal1, Lara E Coelho2, Paula M Luz2, Jesse L Clark1, Raquel B De Boni2, Sandra W Cardoso2, Valdilea G Veloso2, Jordan E Lake1,3, Beatriz Grinsztejn2.   

Abstract

Background: Obesity rates are increasing among HIV-infected individuals, but risk factors for obesity development on ART remain unclear.
Objectives: In a cohort of HIV-infected adults in Rio de Janeiro, Brazil, we aimed to determine obesity rates before and after ART initiation and to analyse risk factors for obesity on ART.
Methods: We retrospectively analysed data from individuals initiating ART between 2000 and 2015. BMI was calculated at baseline (time of ART initiation). Participants who were non-obese at baseline and had ≥90 days of ART exposure were followed until the development of obesity or the end of follow-up. Obesity incidence rates were estimated using Poisson regression models and risk factors were assessed using Cox regression models.
Results: Of participants analysed at baseline (n = 1794), 61.3% were male, 48.3% were white and 7.9% were obese. Among participants followed longitudinally (n = 1567), 66.2% primarily used an NNRTI, 32.9% a PI and 0.9% an integrase strand transfer inhibitor (INSTI); 18.3% developed obesity and obesity incidence was 37.4 per 1000 person-years. In multivariable analysis, the greatest risk factor for developing obesity was the use of an INSTI as the primary ART core drug (adjusted HR 7.12, P < 0.0001); other risk factors included younger age, female sex, higher baseline BMI, lower baseline CD4+ T lymphocyte count, higher baseline HIV-1 RNA, hypertension and diabetes mellitus. Conclusions: Obesity following ART initiation is frequent among HIV-infected adults. Key risk factors include female sex, HIV disease severity and INSTI use. Further research regarding the association between INSTIs and the development of obesity is needed.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29722811      PMCID: PMC6054231          DOI: 10.1093/jac/dky145

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  29 in total

1.  Dolutegravir and weight gain: an unexpected bothering side effect?

Authors:  Amélie Menard; Line Meddeb; Herve Tissot-Dupont; Isabelle Ravaux; Catherine Dhiver; Saadia Mokhtari; Christelle Tomei; Philippe Brouqui; Philippe Colson; Andreas Stein
Journal:  AIDS       Date:  2017-06-19       Impact factor: 4.177

2.  Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.

Authors:  Jamison Norwood; Megan Turner; Carmen Bofill; Peter Rebeiro; Bryan Shepherd; Sally Bebawy; Todd Hulgan; Stephen Raffanti; David W Haas; Timothy R Sterling; John R Koethe
Journal:  J Acquir Immune Defic Syndr       Date:  2017-12-15       Impact factor: 3.731

3.  Early mortality and cause of deaths in patients using HAART in Brazil and the United States.

Authors:  Beatriz Grinsztejn; Valdilea G Veloso; Ruth K Friedman; Ronaldo I Moreira; Paula M Luz; Dayse P Campos; José H Pilotto; Sandra W Cardoso; Jeanne C Keruly; Richard D Moore
Journal:  AIDS       Date:  2009-10-23       Impact factor: 4.177

4.  Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons.

Authors:  Wanda Lakey; Lan-Yan Yang; William Yancy; Shein-Chung Chow; Charles Hicks
Journal:  AIDS Res Hum Retroviruses       Date:  2012-11-07       Impact factor: 2.205

5.  Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s.

Authors:  Grace A McComsey; Carlee Moser; Judith Currier; Heather J Ribaudo; Pawel Paczuski; Michael P Dubé; Theodoros Kelesidis; Jennifer Rothenberg; James H Stein; Todd T Brown
Journal:  Clin Infect Dis       Date:  2016-01-20       Impact factor: 9.079

6.  Trends and risk factors for obesity among HIV positive Nigerians on antiretroviral therapy.

Authors:  L O Ezechi; Z A Musa; V O Otobo; I E Idigbe; O C Ezechi
Journal:  Ceylon Med J       Date:  2016-06

7.  Overweight and obesity as determinants of cardiovascular risk: the Framingham experience.

Authors:  Peter W F Wilson; Ralph B D'Agostino; Lisa Sullivan; Helen Parise; William B Kannel
Journal:  Arch Intern Med       Date:  2002-09-09

8.  Factors associated with tobacco smoking and cessation among HIV-infected individuals under care in Rio de Janeiro, Brazil.

Authors:  Thiago S Torres; Paula M Luz; Monica Derrico; Luciane Velasque; Eduarda Grinsztejn; Valdiléa G Veloso; Sandra W Cardoso; Marília Santini-Oliveira; Beatriz Grinsztejn; Raquel Brandini De Boni
Journal:  PLoS One       Date:  2014-12-23       Impact factor: 3.240

9.  High prevalence of being Overweight and Obese HIV-infected persons, before and after 24 months on early ART in the ANRS 12136 Temprano Trial.

Authors:  Calixte Guehi; Anani Badjé; Delphine Gabillard; Eric Ouattara; Serge Olivier Koulé; Raoul Moh; Didier Ekouevi; Hugues Ahibo; Jean Baptiste N'Takpé; Gérard Kouamé Menan; Nina Deschamps; Jerôme Lecarrou; Serge Eholié; Xavier Anglaret; Christine Danel
Journal:  AIDS Res Ther       Date:  2016-02-25       Impact factor: 2.250

10.  Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada.

Authors:  Hasina Samji; Angela Cescon; Robert S Hogg; Sharada P Modur; Keri N Althoff; Kate Buchacz; Ann N Burchell; Mardge Cohen; Kelly A Gebo; M John Gill; Amy Justice; Gregory Kirk; Marina B Klein; P Todd Korthuis; Jeff Martin; Sonia Napravnik; Sean B Rourke; Timothy R Sterling; Michael J Silverberg; Stephen Deeks; Lisa P Jacobson; Ronald J Bosch; Mari M Kitahata; James J Goedert; Richard Moore; Stephen J Gange
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

View more
  48 in total

Review 1.  Initial Antiretroviral Therapy in an Integrase Inhibitor Era: Can We Do Better?

Authors:  Sean G Kelly; Mary Clare Masters; Babafemi O Taiwo
Journal:  Infect Dis Clin North Am       Date:  2019-06-22       Impact factor: 5.982

Review 2.  Obesity and Weight Gain in Persons with HIV.

Authors:  Samuel S Bailin; Curtis L Gabriel; Celestine N Wanjalla; John R Koethe
Journal:  Curr HIV/AIDS Rep       Date:  2020-04       Impact factor: 5.071

3.  Obesity and Fat Metabolism in Human Immunodeficiency Virus-Infected Individuals: Immunopathogenic Mechanisms and Clinical Implications.

Authors:  Catherine Godfrey; Andrew Bremer; Diana Alba; Caroline Apovian; John R Koethe; Suneil Koliwad; Dorothy Lewis; Janet Lo; Grace A McComsey; Allison Eckard; Suman Srinivasa; Janine Trevillyan; Clovis Palmer; Steven Grinspoon
Journal:  J Infect Dis       Date:  2019-07-02       Impact factor: 5.226

4.  Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.

Authors:  Kassem Bourgi; Peter F Rebeiro; Megan Turner; Jessica L Castilho; Todd Hulgan; Stephen P Raffanti; John R Koethe; Timothy R Sterling
Journal:  Clin Infect Dis       Date:  2020-03-17       Impact factor: 9.079

5.  Antiretroviral Therapy Initiation Is Associated With Decreased Visceral and Subcutaneous Adipose Tissue Density in People Living With Human Immunodeficiency Virus.

Authors:  Paula Debroy; Jordan E Lake; Carlee Moser; Maxine Olefsky; Kristine M Erlandson; Ann Scherzinger; James H Stein; Judith S Currier; Todd T Brown; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2021-03-15       Impact factor: 9.079

6.  Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077.

Authors:  Raphael J Landovitz; Sahar Z Zangeneh; Gordon Chau; Beatriz Grinsztejn; Joseph J Eron; Halima Dawood; Manya Magnus; Albert Y Liu; Ravindre Panchia; Mina C Hosseinipour; Ryan Kofron; David A Margolis; Alex Rinehart; Adeola Adeyeye; David Burns; Marybeth McCauley; Myron S Cohen; Judith S Currier
Journal:  Clin Infect Dis       Date:  2020-01-02       Impact factor: 9.079

Review 7.  Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus.

Authors:  Jordan E Lake; Turner Overton; Susanna Naggie; Mark Sulkowski; Rohit Loomba; David E Kleiner; Jennifer C Price; Kara W Chew; Raymond T Chung; Kathleen E Corey
Journal:  Clin Gastroenterol Hepatol       Date:  2020-10-16       Impact factor: 11.382

Review 8.  HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety.

Authors:  Kimberly K Scarsi; Joshua P Havens; Anthony T Podany; Sean N Avedissian; Courtney V Fletcher
Journal:  Drugs       Date:  2020-11       Impact factor: 9.546

9.  Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV.

Authors:  Maj David A Kline; Colton Daniels; Xiaohe Xu; Thankam Sunil; Anuradha Ganesan; Brian K Agan; Rhonda E Colombo; Karl C Kronmann; Jason M Blaylock; Jason F Okulicz; A Elizabeth Markelz
Journal:  Mil Med       Date:  2021-02-26       Impact factor: 1.437

10.  Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study.

Authors:  Bruno Emond; Carmine Rossi; Aurélie Côté-Sergent; Keith Dunn; Patrick Lefebvre; Marie-Hélène Lafeuille; Prina Donga
Journal:  J Health Econ Outcomes Res       Date:  2021-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.